FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Anti-dementia medications – fighting a losing battle?

Lekovi u lečenju demencija - unapred izgubljena bitka?

Thumbnail
2020
Anti-dementia_medications_pub_2020.pdf (269.8Kb)
Authors
Micov, Ana
Pecikoza, Uroš
Article (Published version)
Metadata
Show full item record
Abstract
Alzheimer’s disease (AD), the most common cause of dementia, is growing health, social and economic issue because of the increasing number of sufferers, limited efficacy of available treatment options, and high total healthcare costs. It is clinically characterized by cognitive and behavioral impairments, both of which need to be treated appropriately to improve patients’ quality of life and their caregivers as well. Currently, available anti-dementia medications provide only modest and transient cognitive benefits. Donepezil, rivastigmine and galantamine (cholinesterase inhibitors) are indicated for the symptomatic management of mild to moderately severe AD, while memantine (NMDA glutamate receptors antagonist) is recommended for moderate-to-severe AD. A special focus on behavioral symptoms (e.g. anxiety, depression, aggression) management is required as they cause great suffering in patients/caregivers. The use of medications that can impair cognitive f...unction, such as drugs with anticholinergic activity, should be avoided in patients with dementia. Additionally, interventions that could delay or prevent dementia onset in some subjects are focused on minimizing modifiable risk factors (hypertension, diabetes, depression) and maximizing protective factors (physical activity, healthy diet, leisure, and social activities). The treatment of AD remains a challenge.

Alzheimer-ova bolest (AB), najčešći oblik demencije, rastući je zdravstveni, socijalni i ekonomski problem zbog sve većeg broja obolelih, nedovoljne efikasnosti postojećih terapijskih mera, kao i velikih ukupnih troškova nege. Klinički se manifestuje smanjenjem kognitivnih funkcija i poremećajima ponašanja, koje treba adekvatno lečiti kako bi se popravio kvalitet života obolelih i njihovih negovatelja. Raspoloživi lekovi za lečenje demencija ostvaruju umereno i prolazno poboljšanje kognitivnih funkcija. Donepezil, rivastigmin i galantamin (inhibitori holinesteraza) su indikovani kao simptomatska terapija blage do umereno teške forme AB, dok se memantin (antagonist glutamatergičkih NMDA receptora) preporučuje za lečenje umerene do teške AB. Poseban aspekt lečenja predstavlja terapija bihejvioralnih simptoma (anksioznost, depresija, agresivnost), koji su veliki problem za pacijente i negovatelje. Trebalo bi izbegavati primenu lekova koji nepovoljno utiču na kogniciju, kao što su lekovi s...a antiholinegičkim dejstvom, kod pacijenata sa demencijom. Dodatno, kontrola promenljivih faktora rizika (hipertenzija, dijabetes, depresija) i usvajanje protektivnih faktora (fizička aktivnost, zdrava ishrana, socijalne aktivnosti i aktivnosti u slobodno vreme) možda može da spreči ili odloži pojavu demencije kod izvesnih ljudi. Lečenje AB i dalje je veliki izazov.

Keywords:
Alzheimer’s disease / donepezil / rivastigmine / galantamine / memantine / Alzheimer-ova bolest / rivastigmin / galantamin / memantin / uloga farmaceuta
Source:
Arhiv za farmaciju, 2020, 70, 2, 55-68
Publisher:
  • Beograd : Savez farmaceutskih udruženja Srbije
  • Pharmaceutical Association of Serbia

DOI: 10.5937/arhfarm2002055M

ISSN: 0004-1963

Scopus: 2-s2.0-85085878784
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3599
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Micov, Ana
AU  - Pecikoza, Uroš
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3599
AB  - Alzheimer’s disease (AD), the most common cause of dementia, is growing health, social and economic issue because of the increasing number of sufferers, limited efficacy of available treatment options, and high total healthcare costs. It is clinically characterized by cognitive and behavioral impairments, both of which need to be treated appropriately to improve patients’ quality  of  life  and  their  caregivers  as  well.  Currently,  available  anti-dementia  medications provide only modest and transient cognitive benefits. Donepezil, rivastigmine and galantamine (cholinesterase inhibitors) are indicated for the symptomatic management of mild to moderately severe  AD,  while  memantine  (NMDA  glutamate  receptors  antagonist)  is  recommended  for moderate-to-severe  AD.  A  special  focus  on  behavioral  symptoms  (e.g.  anxiety,  depression, aggression) management is required as they cause great suffering in patients/caregivers. The use of medications that can impair cognitive function, such as drugs with anticholinergic activity, should  be  avoided  in  patients  with  dementia.  Additionally,  interventions  that  could  delay  or prevent  dementia  onset  in  some  subjects  are  focused  on  minimizing  modifiable  risk  factors (hypertension,  diabetes,  depression)  and  maximizing  protective factors  (physical  activity, healthy diet, leisure, and social activities). The treatment of AD remains a challenge.
AB  - Alzheimer-ova bolest (AB), najčešći oblik demencije, rastući je zdravstveni, socijalni i ekonomski problem zbog sve većeg broja obolelih, nedovoljne efikasnosti postojećih terapijskih mera, kao i velikih ukupnih troškova nege. Klinički se manifestuje smanjenjem kognitivnih funkcija i poremećajima ponašanja, koje treba adekvatno lečiti kako bi se popravio kvalitet života obolelih i njihovih negovatelja. Raspoloživi lekovi za lečenje demencija ostvaruju umereno i prolazno poboljšanje kognitivnih funkcija. Donepezil, rivastigmin i galantamin (inhibitori holinesteraza) su indikovani kao simptomatska terapija blage do umereno teške forme AB, dok se memantin (antagonist glutamatergičkih NMDA receptora) preporučuje za lečenje umerene do teške AB. Poseban aspekt lečenja predstavlja terapija bihejvioralnih simptoma (anksioznost, depresija, agresivnost), koji su veliki problem za pacijente i negovatelje. Trebalo bi izbegavati primenu lekova koji nepovoljno utiču na kogniciju, kao što su lekovi sa antiholinegičkim dejstvom, kod pacijenata sa demencijom. Dodatno, kontrola promenljivih faktora rizika (hipertenzija, dijabetes, depresija) i usvajanje protektivnih faktora (fizička aktivnost, zdrava ishrana, socijalne aktivnosti i aktivnosti u slobodno vreme) možda može da spreči ili odloži pojavu demencije kod izvesnih ljudi. Lečenje AB i dalje je veliki izazov.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Anti-dementia medications –  fighting a losing battle?
T1  - Lekovi u lečenju demencija - unapred izgubljena bitka?
VL  - 70
IS  - 2
SP  - 55
EP  - 68
DO  - 10.5937/arhfarm2002055M
ER  - 
@article{
author = "Micov, Ana and Pecikoza, Uroš",
year = "2020",
abstract = "Alzheimer’s disease (AD), the most common cause of dementia, is growing health, social and economic issue because of the increasing number of sufferers, limited efficacy of available treatment options, and high total healthcare costs. It is clinically characterized by cognitive and behavioral impairments, both of which need to be treated appropriately to improve patients’ quality  of  life  and  their  caregivers  as  well.  Currently,  available  anti-dementia  medications provide only modest and transient cognitive benefits. Donepezil, rivastigmine and galantamine (cholinesterase inhibitors) are indicated for the symptomatic management of mild to moderately severe  AD,  while  memantine  (NMDA  glutamate  receptors  antagonist)  is  recommended  for moderate-to-severe  AD.  A  special  focus  on  behavioral  symptoms  (e.g.  anxiety,  depression, aggression) management is required as they cause great suffering in patients/caregivers. The use of medications that can impair cognitive function, such as drugs with anticholinergic activity, should  be  avoided  in  patients  with  dementia.  Additionally,  interventions  that  could  delay  or prevent  dementia  onset  in  some  subjects  are  focused  on  minimizing  modifiable  risk  factors (hypertension,  diabetes,  depression)  and  maximizing  protective factors  (physical  activity, healthy diet, leisure, and social activities). The treatment of AD remains a challenge., Alzheimer-ova bolest (AB), najčešći oblik demencije, rastući je zdravstveni, socijalni i ekonomski problem zbog sve većeg broja obolelih, nedovoljne efikasnosti postojećih terapijskih mera, kao i velikih ukupnih troškova nege. Klinički se manifestuje smanjenjem kognitivnih funkcija i poremećajima ponašanja, koje treba adekvatno lečiti kako bi se popravio kvalitet života obolelih i njihovih negovatelja. Raspoloživi lekovi za lečenje demencija ostvaruju umereno i prolazno poboljšanje kognitivnih funkcija. Donepezil, rivastigmin i galantamin (inhibitori holinesteraza) su indikovani kao simptomatska terapija blage do umereno teške forme AB, dok se memantin (antagonist glutamatergičkih NMDA receptora) preporučuje za lečenje umerene do teške AB. Poseban aspekt lečenja predstavlja terapija bihejvioralnih simptoma (anksioznost, depresija, agresivnost), koji su veliki problem za pacijente i negovatelje. Trebalo bi izbegavati primenu lekova koji nepovoljno utiču na kogniciju, kao što su lekovi sa antiholinegičkim dejstvom, kod pacijenata sa demencijom. Dodatno, kontrola promenljivih faktora rizika (hipertenzija, dijabetes, depresija) i usvajanje protektivnih faktora (fizička aktivnost, zdrava ishrana, socijalne aktivnosti i aktivnosti u slobodno vreme) možda može da spreči ili odloži pojavu demencije kod izvesnih ljudi. Lečenje AB i dalje je veliki izazov.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije, Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Anti-dementia medications –  fighting a losing battle?, Lekovi u lečenju demencija - unapred izgubljena bitka?",
volume = "70",
number = "2",
pages = "55-68",
doi = "10.5937/arhfarm2002055M"
}
Micov, A.,& Pecikoza, U.. (2020). Anti-dementia medications –  fighting a losing battle?. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 70(2), 55-68.
https://doi.org/10.5937/arhfarm2002055M
Micov A, Pecikoza U. Anti-dementia medications –  fighting a losing battle?. in Arhiv za farmaciju. 2020;70(2):55-68.
doi:10.5937/arhfarm2002055M .
Micov, Ana, Pecikoza, Uroš, "Anti-dementia medications –  fighting a losing battle?" in Arhiv za farmaciju, 70, no. 2 (2020):55-68,
https://doi.org/10.5937/arhfarm2002055M . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB